tbuckley/cabot-search huggingface dataset:
Maprotiline and Pulmonary Alveolitis
Authors: Sergio Salmeron, Francois Brenot, Bernardette Rain, Michel Peuchemaur, Philippe Herve, Gerald Simonneau, Pierre Duroux, Bernard Rouveix
Journal: Annals of Internal Medicine (1988)

Letters and Corrections1 November 1988Maprotiline and Pulmonary AlveolitisSergio Salmeron, MD, Francois Brenot, MD, Bernardette Rain, MD, Michel Peuchemaur, MD, Philippe Herve, MD, Gerald Simonneau, MD, Pierre Duroux, MD, Bernard Rouveix, MDSergio Salmeron, MDSearch for more papers by this author, Francois Brenot, MDSearch for more papers by this author, Bernardette Rain, MDSearch for more papers by this author, Michel Peuchemaur, MDSearch for more papers by this author, Philippe Herve, MDSearch for more papers by this author, Gerald Simonneau, MDSearch for more papers by this author, Pierre Duroux, MDSearch for more papers by this author, Bernard Rouveix, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-9-758_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Maprotiline (Ludiomil, Ciba Pharmaceutical Company, Summit, New Jersey) is a new tetracyclic antidepressant agent widely used in the United States and in Europe. The allergic side effects reported have included skin reactions and abnormal blood values (1). We report a case of allergic alveolitis related to maprotiline treatment.A 66-year-old man was hospitalized with fever and dyspnea. The patient was in good health except for mild depression, and he had been taking maprotiline, 75 mg/d, for the previous 2 months. After 3 weeks of treatment, he had a fever (38.2 °C) and malaise. Because of tremors, trihexyphenidyl...References1. Blackwell B. Antidepressant drugs. In: Dukes MNG, ed. Meyler's Side Effects of Drugs. 10th ed. Amsterdam: Elsevier Science Publishing Co.; 1984:24-61. Google Scholar2. Reynolds H. Bronchoalveolar lavage. Am Rev Respir Dis. 1987;135:250-63. MedlineGoogle Scholar3. RouveixGroultLevacher BFM. Activated human lymphocytes secrete a soluble factor that aggregates leukocytes. Cell Immunol. 1986;99:385-94. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Hôpital Claude Bernard Paris France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByToxicidad pulmonar por maprotilina: a propósito de un caso 1 November 1988Volume 109, Issue 9Page: 758-759KeywordsAllergy and immunologyAlveoliBloodDyspneaFeversSkin reaction Issue Published: 1 November 1988 PDF DownloadLoading ...
THE INACTIVATION OF THE VIRUS OF LYMPHOCYTIC CHORIOMENINGITIS BY SOAPS
Authors: C. Chester Stock, Thomas Francis
Journal: The Journal of Experimental Medicine (1943)

The capacities of certain compounds at pH 7.3–7.5 to inactivate the virus of lymphocytic choriomeningitis have been demonstrated. Among the more effective substances were the fatty acids chaulmoogric, linolic, linolenic, myristic, oleic, and ricinolic, and the detergents zephiran, duponol LS, and aerosol OT. Upon the oleic acid inactivation of the virus, studies have been made of such variables as pH, rate of inactivation, and relative amounts of virus and oleate for removal of the infectivity. The rôle of oxidation in the process was determined as negligible. Attempts to recover infectious virus from oleate-inactivated mixtures have been unsuccessful. It has been found that neither oleate nor ether-inactivated virus was capable of producing immunity in mice under the experimental conditions in which untreated virus induced a moderate immunity.
Serum total IgE and specific IgE to D. pteronyssinus, but not eosinophilic cationic protein (ECP), are more likely to be elevated in elderly asthmatics
Authors: M.J. King, S. Bukantz, S. Phillips, S.S. Mohapatra, T.S. Randall, R.F. Lockey
Journal: Journal of Allergy and Clinical Immunology (2003)
Ethnic Disparities in the Treatment of Stage I Non–Small Cell Lung Cancer
Authors: Juan P. Wisnivesky, Thomas McGinn, Claudia Henschke, Paul Hebert, Michael C. Iannuzzi, Ethan A. Halm
Journal: American Journal of Respiratory and Critical Care Medicine (2005)

Important variations exist in the treatment of non-small cell lung cancer. Because resection is the most effective treatment for patients with early disease, disparities in surgical rates can generate considerable differences in outcomes.We analyzed data from a national population-based registry to evaluate disparities in the treatment of Hispanic and white patients with stage I lung cancer and to assess the extent to which these inequalities explain survival differences.This study included 16,036 Hispanic and white patients with stage I lung cancer diagnosed between 1991 and 2000. Cases were identified from the Surveillance, Epidemiology, and End Results registry. Survival was compared among white and Hispanics using Kaplan-Meier curves. Stratified survival curves and Cox regression were used to evaluate whether inequalities in stage (IA vs. IB) and resection could explain survival differences.Hispanics had worse overall and lung cancer-specific survival compared with whites (p = 0.04 and 0.008, respectively). Five-year lung cancer survival was 54% for Hispanics versus 62% for whites. Hispanics were more frequently diagnosed with stage IB disease (p = 0.0002) and less likely to undergo resection (p = 0.03). Among resected patients, survival was similar for the two groups, as it was among those who did not undergo unresection. After adjusting for surgery and stage, there was no difference in survival between groups.Hispanics with stage I lung cancer had worse survival as compared with whites. These disparities are largely explained by lower rates of resection and higher probability of diagnosis at stage IB. Future work must delineate why Hispanics are receiving less surgery.
Life, death, the unfolded protein response and apoptosis
Authors: A KNOWLTON
Journal: Cardiovascular Research (2006)

See article by Nickson et al.  [1]  (pages 48–56) in this issue .

The unfolded protein response (UPR) occurs in cells in response to accumulation of unfolded proteins in the endoplasmic reticulum (ER). When unfolded protein accumulates secondary to a mild stress, universal protein synthesis is inhibited, but then resumes upon recovery. In contrast, a more severe or persistent stress would lead to apoptosis. UPR has not been extensively studied in the heart, though it has been described recently in association with some disease states such as hypertrophy and ischemia. In the current issue, Nickson et al. report the role of p53-upregulated modulator of apoptosis (PUMA) in the apoptotic response to UPR in neonatal rat cardiac myocytes [1].

Nickson et al. found that UPR induced by either tunicamycin, which blocks glycosylation, or by thapsigargin, which reduces ER calcium, upregulated expression of PUMA beginning at 8 h for mRNA with marked increase in PUMA protein observed at 12 h, and returned to normal by 48 h in isolated rat neonatal cardiomyocytes [1]. Induction of the UPR resulted in apoptosis, which was manifest by 24 h and maximal by 48 h, with 40 to 70% of … 

*Molecular and Cellular Cardiology, Cardiovascular Division, University of California, One Shields Avenue, Davis, CA 95616, Davis, CA, United States. Tel.: +1 530 752 5461; fax: +1 530 754 7167. Email address: aaknowlton{at}ucdavis.edu
Anticoagulation for Embolic Stroke
Authors: John Maher
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABC of spinal cord injury: radiological investigations.
Authors: S K Morcos, A Ouf
Journal: BMJ (1986)

and there are a number of papers proposing selection criteria for gall stone pancreatitis and endoscopic retrograde cloJngiopancreatography on the basis of clinical, biohemical, and sonographic criteria.4Butgiven the possibility of a gall stone aetiology, endoscopic retrograde cholangiopancreatography and endoscopic papillotomy are reasonable options in the management of acute pancreatitis.
Volume of Infusion Controller and Delayed Vasopressor Effect
Authors: ADRIENNE D. SPIGELMAN
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 September 1983Volume of Infusion Controller and Delayed Vasopressor EffectADRIENNE D. SPIGELMAN, PHARM. D., DAVID M. ANGARAN, M.S.ADRIENNE D. SPIGELMAN, PHARM. D.Search for more papers by this author, DAVID M. ANGARAN, M.S.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-99-3-415_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The critically ill patient often needs a vasopressor for hemodynamic support. In addition, because fluids are often limited to such patients, higher concentrations of the various agents are used to help maintain their hemodynamic balance. When the new concentrated fluid is hung, the intravenous tubing is frequently not changed but the tubing already threaded through the infusion controller is used. This tubing contains a volume of fluid of the lower concentration and some time passes before this volume is cleared from the tubing and the patient receives the increased dose. This fact must be kept in mind... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: United Hospitals of Saint Paul Saint Paul, MN 55102 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1983Volume 99, Issue 3Page: 415-416KeywordsAttentionHemodynamicsVasopressors Issue Published: 1 September 1983 PDF DownloadLoading ...
Pocket computers: a new aid to nutritional support.
Authors: C M Colley, A Fleck, J P Howard
Journal: BMJ (1985)

A program has been written to run on a pocket computer (Sharp PC-1500) that can be used at the bedside to predict the nutritional requirements of patients with a wide range of clinical conditions. The predictions of the program showed good correlation with measured values for energy and nitrogen requirements. The program was used, with good results, in the management of over 100 patients needing nutritional support. The calculation of nutritional requirements for each patient individually facilitates more appropriate treatment and may also produce financial savings when compared with administration of a standard feeding regimen to all patients.
Circadian variations in ischemic threshold and their relation to the occurrence of ischemic episodes.
Authors: J Benhorin, S Banai, M Moriel, A Gavish, A Keren, S Stern, D Tzivoni
Journal: Circulation (1993)

The occurrence of ischemic episodes during daily activity has been reported to exhibit a bimodal circadian distribution, yet its relation to the ischemic threshold (heart rate at 1-mm ST segment depression) has not been explored.To determine whether the ischemic threshold during daily activity exhibits a circadian pattern that might relate to the frequency of occurrence of ischemic episodes, we studied the time of occurrence and the heart rate at onset of ischemia in 1,371 ischemic episodes recorded in 41 patients with stable coronary disease, positive exercise testing, and repeated ischemic episodes during ambulatory ECG monitoring (AEM). All patients had 7 days of AEM; 23 were off any anti-ischemic therapy, while 18 were on low dose of beta-blockers. The occurrence of ischemic episodes exhibited the typical bimodal circadian distribution with a prominent peak between 7:00 and 11:00 AM and a second less prominent peak between 6:00 and 9:00 PM. The threshold of myocardial ischemia exhibited a different single-peaked circadian distribution; it was lowest between 1:00 and 3:00 AM and highest between 10 AM and 1 PM. Time series analyses indicated a strong hour-by-hour trend of each of the two circadian distributions, whereas the two series cross-correlated maximally at a lag of zero hours (p < 0.01), indicating a complex interplay between myocardial oxygen demand and supply in determining the occurrence of ischemic episodes during daily activity. The morning increase in the frequency of ischemic episodes could not be attributed to a reduced threshold but rather to an increase in demand. The low threshold at night-time might probably indicate that the mechanism of ischemia during these hours is reduced coronary flow due to increased coronary tone. Secondary analyses for several predefined patients' subsets gave similar results. Patients who received low-dose beta-blockers maintained the bimodal circadian distribution of the occurrence of ischemic episodes, whereas the ischemic threshold exhibited a constant pattern with no circadian changes.Our results demonstrate that myocardial oxygen demand is a major determinant of daily ischemia, yet changes in the ischemic threshold that probably reflect dynamic changes in coronary tone play also an important role. The relative contribution of increased demand and decreased threshold to the genesis of ischemic episodes during daily activity can be assessed by AEM and may help to optimize medical therapy.
Pulmonary function changes in lung-cancer patients treated with radiation with or without carboplatin.
Authors: H J Groen, T W van der Mark, A H van der Leest, E G de Vries, N H Mulder
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

In order to examine changes in pulmonary function in patients with locally advanced non-small-cell lung cancer (NSCLC) before, during, and after standard radiotherapy or combined chemoradiotherapy, we conducted a prospective study involving patients with such cancer, who were treated with radiation alone or with concurrent radiation and carboplatin from October 1992 to February 1994 at the University Hospital in Groningen, the Netherlands. Thirty-five patients were treated. Two patients were excluded because of pulmonary emphysema. Pretreatment values of TLC, VC, the gas-transfer coefficient (Kco), the pulmonary diffusing membrane factor (Dm), and pulmonary capillary blood volume (Vcap) were lower than in normal subjects and patients with chemotherapy-naive germ-cell carcinoma who had a similar pulmonary tumor load as the result of hematogenous metastases. The NSCLC patients' reduced Kco was explained by a decrease in Dm, a measure of alveolar-capillary membrane disturbance, and a similar decrease in Vcap. Pretreatment TLC did not correlate with Vcap or Dm, indicating extra- rather than intrapulmonary vascular and lymphatic obstruction as an explanation for the reduced Vcap and Dm. Locally advanced NSCLC was treated with radiation (n = 16) or combined continuous carboplatin infusion and radiation (n = 17). No changes in TLC, VC, Kco, Dm, or Vcap were observed during and 2 wk after the end of either treatment, nor were any differences in pulmonary function observed with the two treatments, indicating an absence of additional acute pulmonary toxicity caused by continuously infused carboplatin in this patient group.(ABSTRACT TRUNCATED AT 250 WORDS)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Authors: Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, Diana Pickert, Jan-Peter Linke, Barbara Hero, Annette Kopp-Schneider, Frank Westermann, Scott M. Ulrich, Andreas von Deimling, Matthias Fischer, Olaf Witt
Journal: Clinical Cancer Research (2008)

Abstract Purpose: The effects of pan–histone deacetylase (HDAC) inhibitors on cancer cells have shown that HDACs are involved in fundamental tumor biological processes such as cell cycle control, differentiation, and apoptosis. However, because of the unselective nature of these compounds, little is known about the contribution of individual HDAC family members to tumorigenesis and progression. The purpose of this study was to evaluate the role of individual HDACs in neuroblastoma tumorigenesis. Experimental Design: We have investigated the mRNA expression of all HDAC1-11 family members in a large cohort of primary neuroblastoma samples covering the full spectrum of the disease. HDACs associated with disease stage and survival were subsequently functionally evaluated in cell culture models. Results: Only HDAC8 expression was significantly correlated with advanced disease and metastasis and down-regulated in stage 4S neuroblastoma associated with spontaneous regression. High HDAC8 expression was associated with poor prognostic markers and poor overall and event-free survival. The knockdown of HDAC8 resulted in the inhibition of proliferation, reduced clonogenic growth, cell cycle arrest, and differentiation in cultured neuroblastoma cells. The treatment of neuroblastoma cell lines as well as short-term-culture neuroblastoma cells with an HDAC8-selective small-molecule inhibitor inhibited cell proliferation and clone formation, induced differentiation, and thus reproduced the HDAC8 knockdown phenotype. Global histone 4 acetylation was not affected by HDAC8 knockdown or by selective inhibitor treatment. Conclusions: Our data point toward an important role of HDAC8 in neuroblastoma pathogenesis and identify this HDAC family member as a specific drug target for the differentiation therapy of neuroblastoma.
A case of eruptive keratoacanthoma treated by oral etretinate
Authors: K. YOSHIKAWA, S. HIRANO, T. KATO, N. MIZUNO
Journal: British Journal of Dermatology (2006)

A 63-year-old woman with eruptive keratoacanthomas on sun-exposed skin is reported. Attempts were made to produce lesions by the application of a tumour homogenate to the scratched skin, followed by UV-B irradiation; this was positive in two out of three sites, but these factors were probably non-specific stimuli. Treatment with oral etretinate led to most of the tumours disappearing within a month. Recurrence was seen on stopping the drug. Recommencement of therapy followed by a maintenance dose of 10 mg on alternate days, has been associated with freedom from the skin lesions.
Prevention of diabetic nephropathy with enalapril.
Authors: M. Marre, P. Passa, G. Chatellier, J. Menard
Journal: BMJ (1989)

stores and that those patients with the greatest aluminium burden had an increased mortality after infection.4As most aluminium given to patients with acute renal failure is taken up by soft tissues, including the liver and spleen, but not by bone' and thus enters the reticuloendothelial system it is not surprising that aluminium may have an immunomodulatory role.Although this may be of benefit to the recipient of a renal transplant, aluminium accumulation should be avoided in patients with acute renal failure, in whom sepsis remains a major cause of both morbidity and mortality.
Treatment of Obesity and Diabetes in Mice by Transplant of Gut Cells Engineered to Produce Leptin
Authors: Sarah N Oosman, Ada W Lam, George Harb, Suraj Unniappan, Ni T Lam, Travis Webber, Daniel Bruch, Qiu-Xia Zhang, Gregory S Korbutt, Timothy J Kieffer
Journal: Molecular Therapy (2008)

Leptin injections evoke weight loss by causing a reduction in food consumption and an increase in energy expenditure. Also, the administration of leptin lowers blood glucose levels in some rodent models of diabetes and in humans with lipodystrophy. We explored the therapeutic potential of delivering leptin to obese, diabetic ob/ob mice and to mice fed on a high-fat diet (HFD), by transplanting gut-derived cells engineered to produce leptin, under the regulation of an inducing agent, mifepristone. These cells expressed and released leptin in a mifepristone dose-dependent and time-dependent manner. The engineered cells were either transplanted into the mice under the kidney capsule or were encapsulated in alginate and injected into the intraperitoneal cavity, while mifepristone was delivered by implanting 14-day release pellets. In ob/ob mice, leptin delivery by this method caused a significant reduction in food intake and profound weight loss, which was controllable by adjusting the dose of mifepristone. These transplants also achieved rapid and persistent amelioration of diabetes. However, mice fed on a HFD were resistant to the leptin therapy. These results indicate that gut cells can be modified to express leptin in an inducible manner and that the transplantation of these cells has a therapeutic effect in leptin-deficient mice, but not in mice fed on a HFD. Leptin injections evoke weight loss by causing a reduction in food consumption and an increase in energy expenditure. Also, the administration of leptin lowers blood glucose levels in some rodent models of diabetes and in humans with lipodystrophy. We explored the therapeutic potential of delivering leptin to obese, diabetic ob/ob mice and to mice fed on a high-fat diet (HFD), by transplanting gut-derived cells engineered to produce leptin, under the regulation of an inducing agent, mifepristone. These cells expressed and released leptin in a mifepristone dose-dependent and time-dependent manner. The engineered cells were either transplanted into the mice under the kidney capsule or were encapsulated in alginate and injected into the intraperitoneal cavity, while mifepristone was delivered by implanting 14-day release pellets. In ob/ob mice, leptin delivery by this method caused a significant reduction in food intake and profound weight loss, which was controllable by adjusting the dose of mifepristone. These transplants also achieved rapid and persistent amelioration of diabetes. However, mice fed on a HFD were resistant to the leptin therapy. These results indicate that gut cells can be modified to express leptin in an inducible manner and that the transplantation of these cells has a therapeutic effect in leptin-deficient mice, but not in mice fed on a HFD.
"DRAINAGE OF APICAL ABSCESSES OF TEETH"
Authors: John E. Marriott
Journal: JAMA (1925)

<h3>To the Editor:</h3> —I wish to agree heartily with the communication on this subject (The Journal, January 17, p. 221) by Dr. Byron C. Darling. The great majority of dentists will agree that extraction of abscessed teeth is correct procedure. The thing that attracts my attention in Dr. Darling's letter is the statement that "the further tendency now is to extract all devitalized, pulpless or dead deeth." This is rather confusing nomenclature: A devitalized tooth is a dead tooth, a pulpless tooth is a dead tooth; thus, a dead tooth is either pulpless or devitalized. I think that the dental conception of a dead tooth is one from which the pulp has been removed, and the roots filled. Some dentists, however, still practice mummification of the pulp; and these are dead teeth, with the pulp, although devitalized, still left intact in the root canals. A little farther on, Dr. Darling